The purpose of this study is to define the Maximum tolerated dose of SU14813 when administered as single agent in patients with solid tumors.

Inclusion Criteria:

• Patients with a histologically proven advanced solid malignancy for which no recognized therapy was available or for which standard therapy had failed
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Serum albumin ≥3.0 g/dL and adequate haemopoietic, renal and liver function

Exclusion Criteria:

• Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy or an investigational agent within 4 weeks before the start of study treatment
• Subjects had to have recovered from all prior treatment toxicities, except alopecia, and from any major surgery.